Clinical impact of glycans in platelet and megakaryocyte biology. Blood 2022 Jun 02;139(22):3255-3263
Date
01/12/2022Pubmed ID
35015813Pubmed Central ID
PMC9164739DOI
10.1182/blood.2020009303Scopus ID
2-s2.0-85131270735 (requires institutional sign-in at Scopus site) 4 CitationsAbstract
Humans produce and remove 1011 platelets daily to maintain a steady-state platelet count. The tight regulation of platelet production and removal from the blood circulation prevents anomalies in both processes from resulting in reduced or increased platelet count, often associated with the risk of bleeding or overt thrombus formation, respectively. This review focuses on the role of glycans, also known as carbohydrates or oligosaccharides, including N- and O-glycans, proteoglycans, and glycosaminoglycans, in human and mouse platelet and megakaryocyte physiology. Based on recent clinical observations and mouse models, we focused on the pathologic aspects of glycan biosynthesis and degradation and their effects on platelet numbers and megakaryocyte function.
Author List
Falet H, Rivadeneyra L, Hoffmeister KMAuthor
Herve Falet PhD Associate Professor in the Cell Biology, Neurobiology and Anatomy department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsBlood Platelets
Humans
Megakaryocytes
Mice
Polysaccharides
Thrombocytopenia
